InsidersTradesSigma
Follow the Juno Therapeutics, Inc. stock price and the full management transaction log of the company, a publicly traded company based in United States. Shares are listed on the US market, under the supervision of SEC (Form 4). Market capitalisation: €2.2bn. The latest transaction was filed on 20 January 2016 (Cession). Among the most active insiders: Cassidy Bernard J. All data is free.
Analysts rate Juno Therapeutics, Inc. Strong Buy (bullish), based on 12 analysts. Average price target: US$59.30.
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
2 of 2 declarations
Juno Therapeutics, Inc. is a biopharmaceutical company focused on developing cellular therapies for cancer treatment. It specializes in T cell-based treatments and gene therapies.